Oct 01, 2015 · 2022 ICD-10-PCS Procedure Code 6A600ZZ 2022 ICD-10-PCS Procedure Code 6A600ZZ Phototherapy of Skin, Single 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code ICD-10-PCS 6A600ZZ is a specific/billable code that can be used to indicate a procedure. Code History 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-PCS)
Oct 01, 2021 · Neonatal jaundice, unspecified. 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code Code on Newborn Record. P59.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM P59.9 became effective on October 1, 2021. This is the American ICD-10-CM version of P59.9 - …
icd 10 code for phototherapy of newborn
Oct 01, 2021 · Condition of the integument specific to newborn, unspecified 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code Code on Newborn Record P83.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM P83.9 became effective on October 1, 2021.
Yellow discoloration of the skin; mucous membrane; and sclera in the newborn. It is a sign of neonatal hyperbilirubinemia . Most cases are transient self-limiting (physiological neonatal jaundice) occurring in the first week of life, but some can be a sign of pathological disorders, particularly liver diseases.
P59.9 should be used on the newborn record - not on the maternal record. kernicterus ( P57.-) Jaundice that appears during the neonatal period. In the majority of cases, it appears in the first week of life and is classified as physiologic due to accelerated destruction of erythrocytes and liver immaturity.
Condition of the integument specific to newborn, unspecified 1 P83.9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2021 edition of ICD-10-CM P83.9 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of P83.9 - other international versions of ICD-10 P83.9 may differ.
P83.9 should be used on the newborn record - not on the maternal record. The following code (s) above P83.9 contain annotation back-references. Annotation Back-References. In this context, annotation back-references refer to codes that contain: Applicable To annotations, or. Code Also annotations, or.
There are 4 chief Current Procedural Terminology (CPT) codes for reporting phototherapy services: (1) 96900: actinotherapy (UV light treatment); (2) 96910: photochemotherapy, tar, and UVB (Goeckerman treatment) or petrolatum and UVB; (3) 96912: photochemotherapy and PUVA; and (4) 96913: photochemotherapy (Goeckerman and/or PUVA) for severe photoresponsive dermatoses requiring at least 4 to 8 hours of care under direct supervision of the physician.3
In contrast, photochemotherapy (96910) implies addition of a chemo agent to phototherapy. Despite the somewhat nonspecific nature of the code descriptor, it is apparent that application of photoenhancing agents such as tar, petrolatum, or distillates of petrolatum meet the requirements of 96910. The Coder's Desk Reference for Procedures 2017describes 96910 as "the physician uses photosensitizing chemicals and light rays to treat skin ailments." 6Application of light-enhancing topical products should occur within the office by either staff or the patient. In fact, examination of practice expense data from the Centers for Medicare & Medicaid Services indicated that the 96910 code includes payment for clinical staff time to apply topical products as well as the cost of the topical agent(s).7
The PUVA code 96912 is defined by the use of photosensitizing psoralen medication, which can be administered topically or orally, followed by UVA treatment. In my experience, PUVA has similar performance standards with in-office application of psoralen, if applicable. If application of topical photoenhancing products occurs outside the office, the requirements of photochemotherapy are not met, and 96900 should be reported.
The 96913 code defines prolonged phototherapy service with intensive topical therapy requirements and multiple phototherapy sessions per day.3This code is rarely reported (average of fewer than 100 times in the Medicare population per year), and most insurers do not reimburse this service.
Existing coding guidance for phototherapy indicates that actinotherapy (96900) defines the basic service of treating a patient with a UV light unit.5Actino therapy does not involve application of topical medications while the patient is in the office.
However, rumors of the de mise of phototherapy may be great ly exagger ated. Phototherapy is still one of the safest and most cost-effective treatments for psoriasis and other dermatoses.1 Its use often is a prerequisite for biologic therapy, and it may be the only therapeutic option for certain subsets of patients, such as children, pregnant women, and immunosuppressed patients. Moreover, narrowband UVB technology has breathed new life into phototherapy, with better efficacy and less long-term risk. Although the utilization of psoralen plus UVA (PUVA) light therapy has indeed decreased over the last 2 decades, the use of UVB therapies continues to increase dramatically.2